CSPC PHARMA (01093) announced that the SYS6055 injection, developed by the group, has received approval from the National Medical Products Administration (NMPA) of China to commence clinical trials in the country. This product is the first in vivo CAR-T therapy approved for clinical trials in China; it utilizes a lentiviral vector to directly generate CD19-targeting CAR-T cells within the body, enabling specific recognition and elimination of target cells to achieve therapeutic effects. Compared to traditional CAR-T products, this therapy holds potential advantages in terms of cost, accessibility, and immediacy. Preclinical studies have demonstrated that the product can specifically generate CAR-T cells in vivo, exhibiting significant tumor suppression effects, a favorable safety profile, and benefits in both cost and time, potentially offering a superior treatment option for patients with B-cell lymphomas. The approved clinical indication is for relapsed/refractory aggressive B-cell lymphoma. Furthermore, the product also possesses the potential to treat other CD19-positive B-cell malignancies and autoimmune diseases, indicating substantial clinical development value.